Back HCV Populations

People on Opiate Substitution Therapy Respond Well to AbbVie Hepatitis C Treatment

Nearly all genotype 1 hepatitis C patients with a history of injection drug use who were on stable opiate substitution therapy with methadone or buprenorphine were cured using AbbVie's Viekira Pak regimen plus ribavirin for 12 weeks, according to a Phase 2 study described in the August 2015Journal of Hepatology. No interactions were seen between opiate substitution therapy and the hepatitis C drugs.

alt

Read more:

AASLD 2014: Young Drug Injectors on Opioid Agonist Therapy Have Lower Risk of HCV Infection

Young people who inject drugs (PWID) who undergo opioid agonist maintenance therapy with methadone or buprenorphine have more than a 60% reduction in their risk of acquiring hepatitis C virus (HCV) over time, compared to those with no substance use treatment, according to a study presented Monday at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston. Findings were also published in the October 27 edition of JAMA Internal Medicine.

alt

Read more:

Opioid Maintenance Therapy Linked to Lower Hepatitis C Rates for People Who Inject Drugs

Young drug injectors who undergo opioid agonist maintenance therapy using buprenorphine or methadone have a lower likelihood of becoming infected with hepatitis C virus (HCV) than those who continue injecting or use other types of substance use treatment, according to a study published in the October 27 edition of JAMA Internal Medicine.

alt

Read more: